Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | NOS3 | P29474 | 2/20 | 0.36 |
| ▸ | NOS1 | P29475 | 2/20 | 0.36 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.30 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.30 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.30 |
| ▸ | PLAU | P00749 | 1/20 | 0.30 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27044477 | 0.86 | HCAR2 (0.42) | HCAR2NOS3NOS1SLC22A2SLC22A1 | |
| SCHEMBL25640332 | 0.86 | HCAR2 (0.42) | HCAR2NOS3NOS1SLC22A2SLC22A1 | |
| SCHEMBL25455385 | 0.82 | HCAR2 (0.39) | HCAR2NOS3NOS1 | |
| SCHEMBL27044617 | 0.79 | LMNA (0.42) | HCAR2NOS3NOS1 | |
| SCHEMBL25642229 | 0.79 | ABL1 (0.51) | HCAR2NOS3NOS1 | |
| SCHEMBL25642448 | 0.79 | NOS1 (0.33) | HCAR2NOS3NOS1 | |
| SCHEMBL25455406 | 0.77 | ABL1 (0.43) | HCAR2 | |
| SCHEMBL25455553 | 0.75 | ADRB2 (0.37) | HCAR2HDAC1HDAC6 | |
| SCHEMBL14395820 | 0.73 | HCAR2 (0.52) | HCAR2 | |
| SCHEMBL27047722 | 0.73 | HCAR2 (0.52) | HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025860-A1 | SARS-COV-2 INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | INSILICO MEDICINE IP LIMITED (HK) | 2024-01-25 | — | — | US | disclosed |
| US-11731944-B2 | SARS-CoV-2 inhibitors for treating coronavirus infections | INSILICO MEDICINE IP LIMITED (HK) | 2023-08-22 | — | — | US | disclosed |
| US-20230192624-A1 | SARS-COV-2 INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | INSILICO MEDICINE IP LIMITED (HK) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025860-A1 | SARS-COV-2 INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | ACE2, ACE, SARS1 | HCAR2 675/4885NOS3 1827/4885NOS1 1715/4885 |
| US-20230192624-A1 | SARS-COV-2 INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | ACE2, ACE, SARS1 | HCAR2 675/4885NOS3 1827/4885NOS1 1715/4885 |
| US-11731944-B2 | SARS-CoV-2 inhibitors for treating coronavirus infections | ACE2, ACE, SARS1 | HCAR2 675/4885NOS3 1827/4885NOS1 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.